Egypt, Israel, Lebanon & Saudi Arabia: Clinical Development Profile

PREVIEW

Report Overview

Finding patients to participate in clinical trials is a constant struggle in the pharmaceutical industry. The challenging nature of recruitment leads both sponsors and service providers to consistently explore new geographies to find appropriate patient populations. The largest CROs have made several recent acquisitions and agreements in the Middle East and North Africa region which may indicate that clinical trial activity in the area is poised to increase.

In this report, ISR provides insight into the clinical trial regulation and development environment, sponsor and service provider activities, and population “health status” for Egypt, Israel, Lebanon, and Saudi Arabia. Consider this report a “primer” for learning about clinical trials in the region.

Methodologies: ISR gathered content for this report via an exhaustive secondary research effort and from company profile questionnaires that were distributed to CROs profiled in this report.

46 Report Structure: Charts and Graphs 1. Introduction 2. Health Statistics Q3, 2014 3. Clinical Trial Overview and Trial Metrics Publication Date 4. Domestic CROs capabilities 62 5. Profile of Domestic Clinical Service Providers Pages 6. Domestic Service Provider Contact List

What you will learn in this report: • How population health status, regulations, organizations on conducting clinical trials clinical trial activity, and international and in Egypt, Israel, Lebanon and Saudi Arabia domestic company partnerships make Egypt, • Clinical trial operational metrics for country- Israel, Lebanon, and Saudi Arabia some of the specific clinical studies top emerging global pharmaceutical markets • Compiled lists and contact details for domestic • Insights from domestic service provider and international service providers

How you can use this report: • Understand how Egypt, Israel, Lebanon, and • Understand the legal, logistical, and regulatory Saudi Arabi compare to other countries on details for conducting clinicals trials, and a variety of health condition scales so the illustrate the benefits and drawbacks of reader can consider the areas in which they conducting trials in Egypt, Israel, Lebanon, and may be beneficial as trial sites Saudi Arabia

NEXT: Table of contents and sample pages

Table of Contents

Copyright and Usage Guidelines Company profile responses Methodology and Sources Geographic reach Introduction Therapeutic expertise Egypt Experience by Phase Israel Triumpharma Lebanon Background / History Saudi Arabia IPRC Health Statistics Background / History Clinical Trial Activity Acdima BioCenter Egypt Background / History Clinical trials, by Phase Pharmaceutical Research Unit Study type distribution Background / History Industry-funded study type distribution Molecule CRO Average trial length, by Phase Background / History Average enrollment, by Phase MEK Consulting Israel Background / History Clinical trials, by Phase Therapeutic experience Study type distribution Therapeutic experience by Phase Industry-funded study type distribution Regional experience Average trial length, by Phase Organizational structure Average enrollment, by Phase Clients and studies Lebanon CRA education Clinical trials, by Phase CRA experience Study type distribution ClinServ Industry-funded study type distribution Background / History Average trial length, by Phase Nagy Research Average enrollment, by Phase Background / History Saudi Arabia Examples of clients Clinical trials, by Phase SCIDRE Co. Study type distribution (i.e. interventional) Background / History Industry-funded study type distribution Clinart MENA Average trial length, by Phase Background / History Average enrollment, by Phase Company progress Domestic CROs capabilities chart Interventional studies Domestic Clinical Service Providers Observational studies Atlas Medical Services Domestic Service Provider Contact List Background / History About Industry Standard Research Jordan Center for Pharmaceutical Research Background / History MCT Background / History

Sample Page

Introduction

act with confidence

Introduction

Finding patients to participate in clinical trials is a constant struggle in the pharmaceutical industry� The challenging nature of recruitment leads both sponsors and service providers to consistently explore new geographies to find appropriate patient populations� The largest CROs have made several recent acquisitions and agreements in the Middle East and North Africa region which may indicate that clinical trial activity in the area is poised to increase�

• PAREXEL acquired Istanbul-based service provider Atlas Medical Services in July 2014 with the goal of serving clients who see increasing importance in the region and who are seeking broad range of patient populations and market access� • In March 2014, INC Research expanded its presence in the region by purchasing MEK Consulting, a clinical-monitoring focused CRO based in Lebanon� • Quintiles formed an agreement in February 2012 with Dayarn Pharma, a company specializing in pharmaceutical sales, marketing, regulatory services� The partnership allowed Quintiles and its partners to supply contract sales forces and sales promotion outsourcing services in the region� Quintiles cited growing healthcare spend and demand for services in the region as the primary reasons for forming the partnership�

Industry Standard Research has compiled secondary research and statistics in this new report Egypt, Israel, Lebanon & Saudi Arabia: Clinical Development Profile to provide readers with a primer on clinical trial activity in the aforementioned countries� A high-level overview of current clinical trial figures is provided below:

TrialsTrials conductedconducted TrialsTrials conductedconducted TrialsTrials conductedconducted TrialsTrials conductedconducted only in only in only in onlyonly inin only in only in only in EgyptEgypt IsraelIsrael LebanonLebanon SaudiSaudi ArabiaArabia # of Ongoing TrialsTrials 8585 1,2191,219 1313 6969 # of Ongoing Trials by Phase Phase 0: 4 Phase 0: 7 Phase 0: 0 Phase 0: 2 Phase I: 3 Phase I: 47 Phase I: 0 Phase I: 2 # of Ongoing Industry- Data available in full report Phase II: 13 Phase II: 168 Phase II: 2 Phase II: 11 # of OngoingFunded Trials Trials by Phase Phase III: 16 Phase III: 83 Phase III: 2 Phase III: 12 # of Patients Currently Phase IV: 13 Phase IV: 92 Phase IV: 4 Phase IV: 4 Enrolled in Trials No Phase: 36 No Phase: 822 No Phase: 5 No Phase: 38 # of Ongoing Industry- 9 150 2 1 Funded Trials # of Patients Currently ~30,000 ~208,000 ~1,900 ~16,000 Enrolled in Trials © Industry Standard Research www.ISRreports.com ©2014 | Egypt, Israel, Lebanon & Saudi Arabia: Clinical Development Profile 7

Sample Page

Clinical Trial Activity

act with confidence

Egypt Clinical trials, by Phase Percentages are based on the number of ongoing and recently completed (past two years) trials conducted only in Egypt (N=203)� How to read the table: 3 (4%) of the 85 ongoing trials conducted only in Egypt are Phase I trials�

Egypt Ongoing Recently Total Completed Trials (past two years) Total 85 118 203 Phase 0 4 (5%) 3 (3%) 7 (3%) Phase I 3 (4%) 5 (4%) 8 (4%) Phase II 13 (15%) 20 (17%) 33 (16%) Phase III 16 (19%) 26 (22%) 42 (21%) Phase IV 13 (15%) 14 (12%) 27 (13%) No Phase 36 (42%) 50 (42%) 86 (42%) © Industry Standard Research

Study type distribution

The table represents the number of ongoing and recently completed (past two years) trials conducted only in Egypt by the type of study type listed in ClinicalTrials�gov� How to read the table: 70 (82%) of the 85 ongoing trials are classified in ClinicalTrials�gov as “interventional” trials�

Egypt Ongoing Recently Total Completed Trials (past two years) Total 85 118 203 Interventional 70 (82%) 92 (78%) 162 (80%) Observational 15 (18%) 26 (22%) 41 (20%) Expanded Access - - - © Industry Standard Research

Sample Page

Domestic CROs capabilities

act with confidence

Domestic CROs capabilities Atlas Medical Atlas Pharmac Research for Center Jordan PharmaquestJo Pharma Poseidon MCT Triumpharma IPRC BioCenter Acdima Unit Research Pharmaceutical CRO Molecule MEK Consulting ClinServ Ergomed Research Nagy Scidreco Clinart MENA Atlas Medical Atlas Research Pharmac for Center Jordan PharmaquestJo Poseidon Pharma MCT Triumpharma IPRC Acdima BioCenter Unit Pharmaceutical Research Molecule CRO MEK Consulting ClinServ Ergomed Nagy Research Scidreco Clinart MENA RegionRegion AustraliaAustralia MENAMENA EuropeEurope N.N �Americas Americas RestRest of of Asia Asia JapanJapan RussiaRussia S.S �America America WorldwideWorldwide PhasePhase PreclinicalPreclinical PhasePhase I I PhasePhase II II Phase III Data available in full report Phase III Phase IV Phase IV Post launch Post launch No mention No mention Services Bio Analysis Services Bio Analysis Biostatistics Biostatistics Clinical trial servicesClinical trial services Consulting Consulting Data archiving/ warehousingData archiving/ warehousing Data Management Data Management © Industry Standard Research www.ISRreports.com ©2014 | Egypt, Israel, Lebanon & Saudi Arabia: Clinical Development Profile 35

Ordering Information

To obtain full access to this report, please select one of the following licenses:

Single-user License A single-user license allows access to a single individual user. $750 USD

Site-wide License A site-wide license allows access to organization employees $1,125 USD within a particular geographic site/location (i.e. NYC or London office).

Enterprise-wide An enterprise-wide license allows access to ALL employees in $1,500 USD License an organization – this is the recommended license if a report has widespread relevance throughout an organization.

To purchase the report with a credit card or invoice, simply click on the desired license above to be taken to the report page. If you’d like to inquire about a different payment method or have questions, contact us at [email protected] or +1.919.301.0106.

To schedule a call to discuss this report with one of our analysts, please e-mail us at [email protected].

Save on this, or any ISR Register now report, by • Receive a $250 instant credit towards any ISR report creating a free • Earn 10% credit towards all future purchases • Receive advanced notifications on ISR’s latest reports and free resources account

About Industry Standard Research Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.

For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email [email protected], or follow us on twitter @ISRreports. www.ISRreports.com ©2014 | Preview of: Egypt, Israel, Lebanon & Saudi Arabia: Clinical Development Profile 7 act withTh confidencee ISR Difference Custom-quality syndicated market research

www.ISRreports.com

The Common ISR's Reports vs. Syndicated Report How confident are you?

Research methods

Mostly primary One size fits all; research; usually publically always appropriate vs. available data for the topic vs.

Data Collection

ISR's proprietary data collection Struggle to recruit the right tools and channels support fast, targets and enough of them high quality data collection vs.

Respondents

Sophisticated screening Undisclosed ensures genuine vs. methodologies and decision-makers vs. respondent demographics

Sample Sizes

Often insufficient industry Robust sample sizes that vs. representation that leaves you instill confidence defending results Analysts

Decades of experience Junior analysts capable of means more insights that are reporting numbers immediately usable vs. www.ISRreports.comwww.ISRreports.comwww.ISRreports.comwww.ISRreports.com ©2014 | Previewvs. ©2013 ©2013 of: ©2014 | PreviewEgypt, | Preview | PreviewIsrael, of: Benchmarking of:Lebanon of: Benchmarking Benchmarking & Saudi the Arabia:Pharma the European Pharma Clinical Industry’s InvestigatorIndustry’s Development HEOR HEOR FunctionsPayments ProfileFunctions 10 8